CANDEL THERAPEUTICS INC. - COMMON STOCK

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

08 9 2021 08:00:03 提供 Nasdaq GlobeNewswire

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer

07 9 2021 08:00:02 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces Closing of Initial Public Offering, Including the Partial Exercise of Underwriters’ Option

17 8 2021 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces Pricing of Initial Public Offering

26 7 2021 21:05:38 提供 Nasdaq GlobeNewswire